Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niccola Funel

Showing results (71-80 of 97) with videos related to

Pageof 10
Sort By:
Lancet (London, England)|August 28, 2015
Integrated molecular analysis to investigate the role of microRNAs in pancreatic tumour growth and progressionAdam E Frampton, Leandro Castellano, Teresa Colombo, et al.
Therapeutic Advances in Medical Oncology|June 18, 2019
Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatmentTessa Ya Sung Le Large, Btissame El Hassouni, Niccola Funel, et al.
Oncotarget|April 18, 2018
5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancerFrancesca Toffalorio, Mariacarmela Santarpia, Davide Radice, et al.
Cancer Research|October 3, 2013
Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinomaAmir Avan, Viola Caretti, Niccola Funel, et al.
Plos One|November 17, 2012
High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancerElisa Giovannetti, Arjan van der Velde, Niccola Funel, et al.
JCI Insight|July 8, 2020
Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targetsTessa Ys Le Large, Giulia Mantini, Laura L Meijer, et al.
Plos One|May 26, 2010
Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancerJin-Hyeok Hwang, Johannes Voortman, Elisa Giovannetti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2009
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancerFotios Loupakis, Luca Pollina, Irene Stasi, et al.
Oncotarget|April 19, 2016
Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsiesAdam E Frampton, Jonathan Krell, Mireia Mato Prado, et al.
Nature Communications|August 16, 2019
Author Correction: TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progressionSilvia Ottaviani, Justin Stebbing, Adam E Frampton, et al.
Pageof 10

Showing results (71-80 of 97) with videos related to

Sort By:
Pageof 10
Lancet (London, England)|August 28, 2015
Integrated molecular analysis to investigate the role of microRNAs in pancreatic tumour growth and progressionAdam E Frampton, Leandro Castellano, Teresa Colombo, et al.
Therapeutic Advances in Medical Oncology|June 18, 2019
Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatmentTessa Ya Sung Le Large, Btissame El Hassouni, Niccola Funel, et al.
Oncotarget|April 18, 2018
5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancerFrancesca Toffalorio, Mariacarmela Santarpia, Davide Radice, et al.
Cancer Research|October 3, 2013
Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinomaAmir Avan, Viola Caretti, Niccola Funel, et al.
Plos One|November 17, 2012
High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancerElisa Giovannetti, Arjan van der Velde, Niccola Funel, et al.
JCI Insight|July 8, 2020
Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targetsTessa Ys Le Large, Giulia Mantini, Laura L Meijer, et al.
Plos One|May 26, 2010
Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancerJin-Hyeok Hwang, Johannes Voortman, Elisa Giovannetti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2009
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancerFotios Loupakis, Luca Pollina, Irene Stasi, et al.
Oncotarget|April 19, 2016
Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsiesAdam E Frampton, Jonathan Krell, Mireia Mato Prado, et al.
Nature Communications|August 16, 2019
Author Correction: TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progressionSilvia Ottaviani, Justin Stebbing, Adam E Frampton, et al.
Pageof 10